CAR-T (Autoimmune) Deal Benchmarks in Immunology & Autoimmune

Median Upfront

$914M

Range: $475M - $1.3B

Total Deal Value

$5.0B

Range: $3.1B - $6.9B

Royalty Rate

16.3% - 27.2%

Tiered up to 31.2%

Dev Milestones

$820M

Range: $527M - $1.1B

Model Your Deal

Market Analysis

CAR-T (Autoimmune) therapies in immunology & autoimmune have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 car-t (autoimmune) asset in immunology & autoimmune is $914M, with total deal values reaching $5.0B. Development milestones average $820M, while regulatory milestones contribute $1.4B.

The immunology & autoimmune car-t (autoimmune) landscape is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape. The recommended deal structure allocates approximately 18% to upfront payments and 82% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for car-t (autoimmune) immunology & autoimmune deals range from 16.3% to 27.2% at the base tier, with tiered escalation reaching 20.3%-31.2% on blockbuster sales. Commercial milestones averaging $1.8B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a car-t (autoimmune) immunology & autoimmune licensing deal?

Based on our analysis, Phase 2 car-t (autoimmune) licensing deals in immunology & autoimmune average $914M in upfront payments, with a range of $475M to $1.3B depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for car-t (autoimmune) immunology & autoimmune transactions?

The median total deal value for Phase 2 car-t (autoimmune) assets in immunology & autoimmune is $5.0B, ranging from $3.1B to $6.9B. This includes development milestones ($820M), regulatory milestones ($1.4B), and commercial milestones ($1.8B).

What royalty rates are standard for car-t (autoimmune) deals in immunology & autoimmune?

Base royalty rates for car-t (autoimmune) immunology & autoimmune transactions range from 16.3% to 27.2%, with tiered escalations reaching 20.3%-31.2% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in car-t (autoimmune) immunology & autoimmune deals?

CAR-T (Autoimmune) immunology & autoimmune deals allocate approximately 82% of total deal value to milestones. Development milestones ($820M) make up the largest share, followed by commercial milestones ($1.8B) and regulatory milestones ($1.4B).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

Small Molecule in Immunology & Autoimmune

View

Monoclonal Antibody in Immunology & Autoimmune

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating